ESMO 2014: Sessions of Interest for Reporters

A preliminary selection of regular abstracts and other sessions that are potentially interesting for reporters

Access the ESMO 2014 online programme

Molecular profiling of cancer

Reclassifying cancer through genomics

Challenges and perspectives in matching patient, tumour, platform and drugs

Precision medicine: Panacea or false dawn?

Targeting precision medicine toxicities

Drug registration strategies: how will these change with precision medicine?

Personalised screening: avoiding over-diagnosis and over-treatment


Activating immune response to cancer

Clinical interpretation of response with immunotherapy


Tissue markers for immuno-oncology

Breast cancer

Management of breast cancer in specific populations

Cancer during pregnancy: A case-control analysis of mental development and cardiac functioning of 38 children prenatally exposed to chemotherapy

The spectrum of sensitivity to endocrine therapy in metastatic breast cancer

Residual disease after neoadjuvant therapies

Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Neoadjuvant treatment with docetaxel plus lapatinib (L), trastuzumab (T), or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Gastrointestinal cancer

Neoadjuvant and adjuvant chemotherapy in GI cancers: is there a standard of care or not yet?

Familial cancers

Clinical and ethical issues in cancer genetics

Gynaecological cancers

Emerging molecular targets in gynaecological cancers

Novel Pharmacogenetic Germline Candidates of Bevacizumab-related Survival in the ICON7 Trial of Advanced Stage Ovarian Cancer

Targeted therapy of ovarian cancer: beyond carcinogenesis

Primary surgery or neoadjuvant chemo for ovarian cancer: how to select patients?

Haematological malignancies

Targeting signalling pathways in haematological malignancies: are we close to the end of histo-pathological classification and the chemotherapy era?

Lung cancer

The evolving role of systemic treatment in advanced NSCLC

Reclassifying lung cancer and molecular diagnostic

Anti-tumor activity of alectinib in crizotinib pre-treated ALK-rearranged NSCLC in JP28927 study

MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC)


Immunotherapy or targeted therapy for oncogene addicted melanoma?

Behind treatment combinations in melanoma

Prostate cancer and other genitourinary cancers

Do we need a new taxonomy for prostate cancer?

Beyond tumour heterogeneity: new pathways in kidney cancer

Public Health and Health Economics

Cross-comparison of cancer drug approvals among international regulatory bodies

Risk of Incremental Toxicities And Associated Costs of New Anticancer Drugs: A Meta-Analysis

Prevention and Screening

Prevention and screening

Controversy sessions

Can oncologists manage immunotherapy toxicity?

Proton-beam therapy: Emperor’s new clothes?

Endpoints other than OS are vital for regulatory approval

Access the ESMO 2014 online programme